100 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Stone House Investment Management LLC

Stone House Investment Management LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 100 shares of the company’s stock, valued at approximately $33,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. DT Investment Partners LLC purchased a new stake in shares of Medpace during the 2nd quarter valued at about $41,000. Ashton Thomas Securities LLC purchased a new stake in shares of Medpace in the 3rd quarter worth $37,000. Ashton Thomas Private Wealth LLC bought a new position in Medpace during the 2nd quarter worth about $52,000. Capital Performance Advisors LLP bought a new stake in Medpace during the 3rd quarter valued at $46,000. Finally, International Assets Investment Management LLC purchased a new position in Medpace in the second quarter valued at about $61,000. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MEDP shares. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Truist Financial decreased their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Robert W. Baird increased their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a report on Monday. UBS Group cut Medpace from a “buy” rating to a “neutral” rating and cut their price objective for the company from $420.00 to $350.00 in a research report on Friday, September 27th. Finally, William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $380.56.

Medpace Stock Up 0.3 %

MEDP stock traded up $0.94 on Wednesday, reaching $336.15. 30,714 shares of the company’s stock were exchanged, compared to its average volume of 283,946. Medpace Holdings, Inc. has a twelve month low of $268.80 and a twelve month high of $459.77. The firm has a market cap of $10.45 billion, a PE ratio of 29.35, a P/E/G ratio of 1.87 and a beta of 1.37. The stock has a fifty day moving average of $339.37 and a 200-day moving average of $372.21.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the firm posted $2.22 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.